WO1998044929A1 - Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses - Google Patents
Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses Download PDFInfo
- Publication number
- WO1998044929A1 WO1998044929A1 PCT/US1998/006869 US9806869W WO9844929A1 WO 1998044929 A1 WO1998044929 A1 WO 1998044929A1 US 9806869 W US9806869 W US 9806869W WO 9844929 A1 WO9844929 A1 WO 9844929A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- glucosamine
- collagen protein
- patient
- hydrolyzed collagen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
Definitions
- the present invention relates to a composition for treatment of degenerative joint diseases, and to a method of treating arthroses.
- Degenerative joint diseases or arthroses are conditions where degenerative changes in cartilage lead to a breakdown in the integrity of the structural matrix of cartilage or tendonous tissues.
- Conventionally referred to as arthritis the complaints associated with the degenerative changes occur most frequently in individuals over 50.
- Arthritis affects over 40 million 15 Americans (1 in 7). 80% of Americans over 50 have arthritis. Over 45, women experience arthritis 10 times more than men. In short, Arthritis is the primary cause of disability in Americans
- Symptoms include early morning stiffness, 20 stiffness following periods of rest, pain that worsens on joint use and loss of joint function.
- Cartilage provides the cushion and frictionless mobility of. joints.
- cartilage is constantly under a process of natural repair and regeneration. 25 Because of overuse, injury or other causes, many individuals overwhelm their body's ability to keep up with the natural process of repair. The result is cartilage that becomes increasing dry and inflexible leading to pain and eventual joint restriction.
- Steroids such as corticosteroids, and other anti-inflammatory materials, such as non-steroidal anti-inflammatory drugs ("NSAIDs") and high doses of aspirin, are widely used for the treatment of these ailments, Pharmocol. Res. Commun. 10:557-569 (1978) by Vidal et al. While these materials often relieve the pain and swelling associated with maladies arising from connective tissue problems, they offer no support for repair processes.
- NSAIDs non-steroidal anti-inflammatory drugs
- NSAIDs may also inhibit the body's own natural healing processes, leading to further deterioration of the connective tissue.
- These prior efforts may be characterized as providing only temporary palliative or symptomatic relief in as much as they furnish no pharmacological support system for the repair and regeneration of connective tissue.
- An object of the present invention is to provide agents for the treatment of arthroses that are suitable for alleviating and curing effects on arthroses.
- a particular object of the present invention is to provide a novel therapeutic composition comprising nutritional elements in a synergistic combination that is effective in promoting the repair and regeneration of joint and connective tissues.
- a further object of the present invention is to provide a method for treating arthritis by administering to a patient in need of such treatment an effective amount of the present novel therapeutic composition.
- HCP hydrolyzed collagen protein
- glucosamine or a therapeutically acceptable salt
- the present therapeutic composition of HCP and glucosamine has a positive effect on connective tissue maintenance and is capable of offering additional nutritional support for osteoporotic individuals.
- the present invention further contemplates a method of treating arthroses and a method of maintaining joint tissue health.
- the present invention offers the surprising benefit of providing a therapeutic composition which supplies co-factors for the repair and regeneration of connecting tissue, such as cartilage, while concurrently functioning as an analgesic, and a method of treatment using such a composition.
- the present composition includes two essential ingredients: hydrolyzed collagen protein in combination with glucosamine and/or pharmacologically acceptable salts thereof, which, in combination, act synergistically to stimulate both collagen and proteoglycan synthesis.
- Hydrolyzed collagen protein particularly enzymatically hydrolyzed collagen having a molecular weight of up to 80 kilodaltons, capable of being synergistically combined with at least one of glucosamine and pharmacologically acceptable inorganic glucosamine salts herein is available, and is generally described in U.S. Patent No. 4,804,745, the complete disclosure of which is incorporated herein by reference.
- the hydrolyzed collagen protein can have a molecular weight in the range of about 1 to about 300 kilodaltons.
- Lower molecular weight fractions of hydrolysed collagen protein in the range of about 1 to 10 kilodaltons can, if desired, be used alone or in combination with one or more higher molecular weight fractions of hydrolyzed collagen protein.
- Higher molecular weight fractions include hydrolyzed collagen protein and fractions thereof in the range of about 100 to 300 kilodaltons. It has been determined that particularly efficient assimilation characteristics and a particularly good efficiency against arthroses, are observable when hydrolyzed collagens having an average molecular weight of from 10,000 to 80,000 (10 to 80 kilodaltons) are employed. Higher molecular weight preparations are generally less readily soluble in cold water. Lower molecular weight products are also more difficult to prepare in acceptable forms for application.
- glucosamine and pharmaceutically acceptable salts thereof are available, and, in general, are described in U.S. Patent No. 5,587,363 and U.S. Patent No. 5,364,845, the complete disclosures of which are incorporated herein by reference.
- Suitable salts include, among others, glucosamine sulfate and glucosamine hydrochloride.
- Glucosamine may, if desired, include or be comprised of crude forms thereof.
- Glucosamine and its pharmaceutically acceptable salts combine well with the hydrolyzed collagen protein base of the composition, providing the primary substrates for both collagen and proteoglycan synthesis.
- Glucosamine is the preferred substrate for proteoglycan synthesis, including chondroitin sulfates and hyaluronic acid.
- the glucosamine is, preferably, in a salt form so as to facilitate its delivery and uptake by the patient.
- the preferred salt forms are glucosamine sulfate and glucosamine hydrochloride.
- patient includes veterinary patients, such as veterinary mammalian patients, and also human patients unless otherwise stated.
- Glucosamine has been shown to be rapidly and almost completely absorbed into humans and animals after oral administration. A significant portion of the ingested glu ⁇ samine localizes to cartilage and joint tissues, where it remains for long time periods. This indicates that oral adrninistration of glucosamine reaches connective tissues, where glucosamine is incorporated into newly-synthesized connective tissue.
- glucosamine can lead to increased synthesis of collagen and glycosaminoglycans from fibroblasts which is the first step in repair of connective tissues.
- Glucosamine and its pharmaceutically acceptable salts have also exhibited reproducible improvement in symptoms and cartilage integrity in humans with osteoarthritis in a series of studies, such Tapadinhas
- the present therapeutic composition manifests a number of unique and unexpected advantages.
- Clinical research in arthroses indicates that the synergistic effects of the therapeutic composition exceed the benefits obtainable from adrrjinistration of the ingredients singly. This unexpected result obtains from effects seen at the level of connective tissue.
- This increase in synthesis is exceptional in that the enzymatic mechanisms related to collagen and glycosaminglycan synthesis are enhanced well beyond normal activity levels.
- chondrocyte inhibitory factors such as cytokines, interferons and prostoglandins may be responsible for this unexpectedly enhanced activity, or that the components themselves may have a catalytic or co-catalytic effect. Additional findings relate to a localized reduction in inflammatory products from activated mononuclear cells known to decrease fibroblast proliferation.
- the present therapeutic composition in principle has the effect of maintaining and re-establishing overall composition of cartilage glycosaminoglycans, in spite of tissue age.
- the data suggest that the proportion of chondroitin sulfate, which generally falls with increasing age, is maintained versus that of keratin sulfate and hyaluronate. Therefore, in vivio, the consistent supplementation with the present therapeutic composition may forestall at least some age-related changes in cartilage composition heretofore considered to affect the ability of proteoglycan elements to aggregate with one another or to interact with collagen.
- Glucosamine sulfate and its pharmaceutically acceptable salts taken supplementary can be used by the patient to produce primarily glycosamineglycans ("GAGs"), and secondarily collagen.
- GAGs glycosamineglycans
- the present therapeutic composition advantageously enables a relative enhancement in GAG synthesis with a concomitant reduction in consumption of glucosamine and its salts in collagen synthesis.
- the present invention offers further advantages over conventional compositions and methods of treatment. Among these, administration of the present therapeutic composition advantageously does not require ever increasing dosages of the essential ingredients during the treatment period. This advantage results because the present therapeutic composition provides an effective balanced combination of analgesia and pharmacological support for the treatment of the underlying disease. Maintenance dosing at a reduced dosage level can, where appropriate, be administered thereafter.
- the present therapeutic composition can be administered to the patient in a number of efficacious forms.
- the present composition can be supplied in a powder form which is at least substantially homogeneous compositionally and has a substantially homogeneous particle size distribution.
- the substantially homogeneous particle size distribution means that as a result of mixing, blending or otherwise effectively combining the at least two essential ingredients, the hydrolyzed collagen protein plus the glucosamine and/or its acceptable salts each have the desired pre-selected particle sizes.
- the two ingredients can be combined and the combined form can be rendered pulverulent such that the particles themselves are substantially homogeneous from the compositional standpoint.
- fluidized bed techniques can be adapted for the preparation of the foregoing powder formulations.
- the scoop form of the composition can be measured out dry, such as with a measuring scoop, for administration to the patient.
- a measuring scoop for administration to the patient.
- the dosage is scooped in dry form and can be added to the veterinary patient's diet, such as in the animal feed.
- the scoop method can also be similarly used.
- the present invention can also be administered to the patient, human or veterinary mammalian patient, in capsule or tablet form. Tablets can, if desired, be coated or uncoated. Suitable tableting procedures include those generally described in Perry's Chemical Engineer's Handbook, page 8-62 to 8- 64 (4 th Edition 1963), Ullmann's Encyclopedia of Industrial Chemistry, volume A19, pages 245-256 (Springer Verlag 1991), Ullmann's Encyclopedia of Industrial Chemistry, volume B2,pages 7-31 to 7-37 (Springer Verlag
- the present therapeutic composition can also be administered in capsule or gel-cap form.
- the size of each dosage and the interval of dosing to the patient effectively determines the size and shape of the tablet or capsule.
- each capsule and each tablet contains both of the present essential ingredients in pre-determined amounts to simplify the patient's treatment regimen.
- the present therapeutic composition can be administered orally. Oral administration is preferred because of convenience to the patient as well as the dosing schedule.
- the composition can be administered in powder form, but is, for at least some patients, more readily administered in solution.
- the solution media can be water or any consumable liquid or beverage.
- the beverage and consumable liquids are non-carbonated, and can, if desired, also be non-alcoholic.
- the therapeutic composition can be provided for administration in the form of a so- called instantized (powdered) formulation for ready swallowing or ready dissolution in the selected liquid for subsequent administration to the patient, or can be provided in pre-mixed solution for immediate use or as a pre-mixed dilutable concentrate.
- the pre-mixed form can be packaged in suitable containers such as, cans, bottles or the like for storage prior to use.
- a predetermined amount of a powdered solid pre-mix formulation can also be packaged in one or more sachets.
- the composition can also be administered in the form of a paste, compact, emulsion, elixir, granules, syrup, lozenges, gum, or candied formulation.
- the two essential ingredients are relatively neutral in taste, and thus they can, if desired, be combined with flavoring materials, sweeteners, and/or aroma ingredients.
- the composition can also include other additives known in the nutritional and pharmaceutical arts such as, for instance, multi-vitamins, minerals, or nutritional elements, among others.
- the composition includes relative amounts of the two essential ingredients.
- compositions are formulated to provide an effective amount of hydrolyzed collagen protein, such as in adrninistration, e.g. dosing, to the patient.
- the hydrolyzed collagen is, in general, dosed so that the patient, human or veterinary mammalian patient, can receive a hydrolyzed collagen dosage in the range of 0.5 to 12 grams.
- An efficient therapy can involve daily doses of from 5 to 12 grams hydrolyzed collagen protein.
- the present compositions are formulated to provide an effective amount of the glucosamine and/or its pharmaceutically acceptable salts, such as in the administration, e.g. dosing, to the patient.
- the dosage is in a range of about 0.25 to 3.0 grams, depending on the patient, human or veterinary, receiving treatment.
- the patent can receive about 0.75 gram to about 2.0 grams of the glucosamine and/or its pharmaceutically acceptable salts.
- the present therapeutic composition is administered to a patient, such as a human patient, in which the daily dosage is about 7 to about 8 grams of hydrolyzed collagen protein in combination with about 1.5 to about 2.0 grams of the glucosamine and/or its pharmaceutically acceptable salts, e.g. in a weight ratio of about 3.5 to about 5.3.
- the relative amounts of effective ingredients within a dose or dosing schedule can be adjusted as appropriate for efficacious administration to veterinary patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54303598A JP2001524080A (en) | 1997-04-10 | 1998-04-09 | Composition comprising hydrolyzed collagen protein and glucosamine for the treatment of arthritis |
AU69545/98A AU6954598A (en) | 1997-04-10 | 1998-04-09 | Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses |
EP98915336A EP0991413A1 (en) | 1997-04-10 | 1998-04-09 | Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4322697P | 1997-04-10 | 1997-04-10 | |
US60/043,226 | 1997-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998044929A1 true WO1998044929A1 (en) | 1998-10-15 |
Family
ID=21926140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006869 WO1998044929A1 (en) | 1997-04-10 | 1998-04-09 | Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0991413A1 (en) |
JP (1) | JP2001524080A (en) |
AU (1) | AU6954598A (en) |
WO (1) | WO1998044929A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001072582A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Functional oral composition |
WO2001093832A2 (en) * | 2000-06-02 | 2001-12-13 | The Procter & Gamble Company | Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
WO2001093833A2 (en) * | 2000-06-02 | 2001-12-13 | The Procter & Gamble Company | Kits and methods for optimizing the efficacy of chondroprotective compositions |
US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
WO2002098449A1 (en) * | 2001-06-01 | 2002-12-12 | Nippon Meat Packers, Inc. | Remedies for joint injury and functional foods |
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
JP2004507490A (en) * | 2000-08-29 | 2004-03-11 | アナスタシアデス,タソース,ピー | Treatment of arthritis and compositions therefor |
WO2008009798A1 (en) * | 2006-07-19 | 2008-01-24 | Bio Serae Laboratoires Sa | Composition based on d-glucosamine, on lactoferrin and on chondroitin sulphate for preventing and/or treating degenerative joint diseases |
WO2018166807A1 (en) * | 2017-03-15 | 2018-09-20 | Rousselot B.V. | Compositions of hydrolyzed collagen peptides and commensal microorganisms and methods thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4804745A (en) * | 1986-07-25 | 1989-02-14 | Deutsche Gelatine-Fabriken Stoess & Co. Gmbh | Agents for the treatment of arthroses |
WO1994022453A1 (en) * | 1993-03-31 | 1994-10-13 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
-
1998
- 1998-04-09 EP EP98915336A patent/EP0991413A1/en not_active Withdrawn
- 1998-04-09 AU AU69545/98A patent/AU6954598A/en not_active Abandoned
- 1998-04-09 JP JP54303598A patent/JP2001524080A/en not_active Withdrawn
- 1998-04-09 WO PCT/US1998/006869 patent/WO1998044929A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4804745A (en) * | 1986-07-25 | 1989-02-14 | Deutsche Gelatine-Fabriken Stoess & Co. Gmbh | Agents for the treatment of arthroses |
WO1994022453A1 (en) * | 1993-03-31 | 1994-10-13 | Nutramax Laboratories, Inc. | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
JP2001072582A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Functional oral composition |
WO2001093832A2 (en) * | 2000-06-02 | 2001-12-13 | The Procter & Gamble Company | Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
WO2001093833A2 (en) * | 2000-06-02 | 2001-12-13 | The Procter & Gamble Company | Kits and methods for optimizing the efficacy of chondroprotective compositions |
WO2001093832A3 (en) * | 2000-06-02 | 2002-04-25 | Procter & Gamble | Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
WO2001093833A3 (en) * | 2000-06-02 | 2002-04-25 | Procter & Gamble | Kits and methods for optimizing the efficacy of chondroprotective compositions |
JP2004507490A (en) * | 2000-08-29 | 2004-03-11 | アナスタシアデス,タソース,ピー | Treatment of arthritis and compositions therefor |
WO2002098449A1 (en) * | 2001-06-01 | 2002-12-12 | Nippon Meat Packers, Inc. | Remedies for joint injury and functional foods |
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
WO2008009798A1 (en) * | 2006-07-19 | 2008-01-24 | Bio Serae Laboratoires Sa | Composition based on d-glucosamine, on lactoferrin and on chondroitin sulphate for preventing and/or treating degenerative joint diseases |
FR2903906A1 (en) * | 2006-07-19 | 2008-01-25 | Bio Serae Lab | COMPOSITION FOR PREVENTING AND / OR TREATING DEGENERATIVE JOINT DISEASES. |
WO2018166807A1 (en) * | 2017-03-15 | 2018-09-20 | Rousselot B.V. | Compositions of hydrolyzed collagen peptides and commensal microorganisms and methods thereof |
US11110147B2 (en) | 2017-03-15 | 2021-09-07 | Rousselot B.V | Collagen hydrolysates as a beneficial prebiotic and their effect on joint inflammation and osteoarthritis |
Also Published As
Publication number | Publication date |
---|---|
JP2001524080A (en) | 2001-11-27 |
EP0991413A1 (en) | 2000-04-12 |
AU6954598A (en) | 1998-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0178602B1 (en) | Treatment for tissue degenerative inflammatory disease | |
Brandt | Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo | |
Moskowitz | Role of collagen hydrolysate in bone and joint disease | |
US4772591A (en) | Method for accelerated wound healing | |
JP2971579B2 (en) | Amino sugar and glycosaminoglycan compositions for the treatment and recovery of connective tissue | |
US6492349B1 (en) | Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue | |
JP5662492B2 (en) | Anti-inflammatory preparation | |
JPS6339821A (en) | Remedy for articulation | |
EP1276485B1 (en) | Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate | |
US6524609B1 (en) | Treating arthritis in animals with dietary supplements | |
CA2652537A1 (en) | Veterinary pharmaceutical compositions for the treatment of pain and inflammation | |
WO1998044929A1 (en) | Composition comprising a hydrolysed collagen protein and glucosamine for the treatment of arthroses | |
AU2009304002B2 (en) | A medicinal product and treatment | |
JP2007522232A (en) | Compositions and methods for use in conditions affecting cartilage | |
US20030125303A1 (en) | Transdermal formulation for repair and maintenance of connective tissue | |
AU767689B2 (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration | |
JP2003155250A (en) | Healthy hood for relieving arthrodynia | |
ES2325392B1 (en) | COMPOSITION FOR THE TREATMENT OF ARTROSIS. | |
US6218433B1 (en) | Use of pharmaceutical composition in the treatment of traumatic arthritis in horses | |
WO2023086283A1 (en) | Method for treating skeletal articulations and composition and uses thereof | |
Singh et al. | A Review on Etiopathogenesis and Medicinal Management of Ante Brachial Deformities in Growing Dogs | |
EP2243478A1 (en) | Pharmaceutical composition combining an antiarthritic agent and an interleukin-1 inhibiting agent, which can be used to control and treat osteoarthritis and related diseases | |
KR20020072491A (en) | An arthritis and arthrosis injury prevention and treatment solution by synergistic action of glucose and amino acid | |
WO2004000364A1 (en) | Preparation containing polydimethylsiloxane for nails, cartilage, bone joint, muscle and tendon disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 543035 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09414825 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998915336 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998915336 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998915336 Country of ref document: EP |